

Curcumin: footprints on cardiac tissue engineering

Original

Curcumin: footprints on cardiac tissue engineering / Kargozar, S.; Baino, F.; Hoseini, S. J.; Verdi, J.; Asadpour, S.; Mozafari, M.. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - ELETTRONICO. - 19:11(2019), pp. 1199-1205. [10.1080/14712598.2019.1650912]

Availability:

This version is available at: 11583/2766432 since: 2019-11-12T17:14:16Z

Publisher:

Taylor and Francis Ltd

Published

DOI:10.1080/14712598.2019.1650912

Terms of use:

openAccess

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

(Article begins on next page)

Curcumin: Footprints on Cardiac Tissue Engineering

Saeid Kargozar^{1,*}, Francesco Baino², Seyed Javad Hoseini³, Shiva Asadpour⁴, Masoud Mozafari^{5,6,7,*}

- ¹. Tissue Engineering Research Group (TERG), Department of Anatomy and Cell Biology, School of Medicine, Mashhad University of Medical Sciences, 917794-8564 Mashhad, Iran
- ². Institute of Materials Physics and Engineering, Applied Science and Technology Department, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Torino, Italy
- ³. Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
- ⁴. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran
- ⁵. Bioengineering Research Group, Nanotechnology and Advanced Materials Department, Materials and Energy Research Center (MERC), PO Box 14155-4777, Tehran, Iran
- ⁶. Cellular and Molecular Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran
- ⁷. Department of Tissue Engineering & Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran

*** Correspondence to:**

S. Kargozar, PhD; (E-mail address: kargozarsaeid@gmail.com)
M. Mozafari, PhD; (E-mail address: mozafari.masoud@gmail.com)

Abstract

Curcumin-based products are extensively being used as therapeutics in the treatment of cardiac disorders; however, there is no specific report on the potential usability of curcumin in cardiac tissue engineering applications. Having anti-oxidant, anti-inflammatory and anti-apoptotic properties, curcumin has been found highly promising for use in reconstructive strategies since it could promote the tissue healing process. Various tissue-engineered constructs containing curcumin (e.g., three dimensional (3D) scaffolds) have been developed for the management of soft tissue damages like wound injuries, and hence there are new hopes for the use of this amazing natural product for cardiac tissue engineering. However, some crucial questions should first be answered, including the optimum dosages of curcumin for promoting cardiac tissue regeneration, the type of carrier used (e.g., polymeric matrices), the preferable release profile, as well as the short- and long-term toxicity in the human body.

Keywords: Curcumin; Cardiac tissue engineering; Cardiac patches; Scaffold; Healing

1. Introduction

Cardiovascular diseases (CVDs) are among the most serious life-threatening disorders worldwide [1]. Myocardial infarction (MI) is commonly caused by the blockage of a coronary artery and leads to a massive cardiomyocyte loss in the heart tissue. Regarding poor regeneration of the heart, the lost cardiomyocytes are usually replaced with fibroblasts, and non-contractible scar tissue is created at the defect site resulting in a reduction in cardiac output. Therefore, the need for reconstructive interventions is absolutely demanded for patients suffering from heart diseases.

After being introduced in the 1980s, tissue engineering (TE) and regenerative medicine have created new hopes for the treatment of CVDs. On this object, researchers from different fields like materials science, medicine, and pharmacology are being trying to develop novel TE-based products to induce and improve the repair and regeneration of the damaged myocardium. The three building blocks of TE strategies are biomaterials (natural and synthetic), cells (differentiated and stem cells), and growth factors (native and recombinant) (see Figure 1) [2-4]. As it has been well-defined, the regeneration process of the heart tissue post-MI takes between six to eight weeks [5]. Hence, the substitutes designed for the replacement of the damaged heart tissue should have the ability to degrade over the regenerative period in order to avoid fibrous capsule formation and chronic inflammatory response in the cardiac tissue [6]. Moreover, a couple of other critical factors should be counted for materials and constructs used for MI reconstructive strategies, including the lack of local and systemic toxicity (i.e., biocompatibility), and the need for electromechanical integration with host myocardium (specifically, a good matching between the mechanical properties of host tissue and implant) [7].

Figure 1. Representative illustration of mechanisms involved in cardiac tissue repair and regeneration. Reproduced from Ref [8].

The use of natural plant products has recently appealed much consideration in TE strategies for soft tissue reconstruction [9]. These materials are considered as relatively inexpensive substances which can promote the wound healing process. Curcumin is one of the most widely-used natural extracts in TE strategies, especially in soft tissue healing. Although curcumin is historically identified as anti-cancer therapeutics due to anti-proliferative effects against multiple cancerous cells and inhibitory activity on the nuclear factor kappa light chain enhancer of activated B cells (NF- κ B) and downstream gene products (e.g., c-myc, Bcl-2, and COX-2) [10-17], this natural substance is recently found as an effective material in soft tissue healing. In this mini-review, we aim to propose curcumin as a great therapeutic natural product for cardiac TE. To the best of the authors' knowledge, it is the first report on the potential usability of curcumin as an additive in tissue-engineered constructs for cardiac regeneration.

2. Curcumin for cardiac tissue engineering

2.1. Exploring the question, weighing the merits

Curcumin, the main curcuminoid of the turmeric rhizome (*Curcuma longa*), is noted for its well-known anti-inflammatory, antioxidative, anti-apoptotic, and cardioprotective effects [18]. There is a large number of *in vitro* and *in vivo* studies showing that curcumin could reduce the generation of reactive oxygen species (ROSs), exert cytoprotective effects, and attenuate oxidative stress and inflammation [19-21].

Several mechanisms are involved in myocardial ischemia, and their role in ischemic myocardial cell injury and death have been well-characterized at the molecular level. As an illustration, the generation of ROSs in myocardial ischemia increases as a result of the loss of surface energy of the substrate [22]. The increased levels of ROSs can cause a variety of cardiomyocyte abnormalities like disturbed contractile activity[23]. Liu et al. clarified that the administration of curcumin (10, 20 or 30 mg/kg/d) as a supplement to rats results in reductions of oxidative stress (3-fold) and infarct size (2.5-fold) as compared to negative control groups [24]. Moreover, the percentage of infarct size in rats receiving curcumin (10, 20 or 30 mg/kg/d) after myocardium ischemia-reperfusion (MIR) showed a significant decrease (from 49.1% to 18.3%) as compared to the curcumin-free ischemia-reperfusion group. The authors proposed that the curcumin intake could reduce the risk of coronary heart disease via inducing JAK2/STAT3 signal pathway, decreasing oxidative damage and inhibiting myocardium apoptosis.

One of the main events occurring post-MI is cell apoptosis at the damaged sites, which causes hindering the ventricular remodeling of the remaining active myocardium [25]. Therefore, reducing apoptosis can be considered as one of the major targets for preventing heart failure progression of patients following MI. On this matter, Geng et al. showed that curcumin could protect cardiac myocytes against apoptosis induced by hypoxia in the most widely used inbred strain of mice, i.e., C57 black 6 (C57BL/6). They reported that curcumin exerts its protective effects via the up-regulation of miR-7a/b and the down-regulation of transcription factor SP1. In addition to decreasing these biochemical parameters, curcumin has been documented to modulate the SIRT3 signaling pathway and, hence, reduce the expression of other apoptotic

markers, like the pro-apoptotic protein Bax and acetylated superoxide dismutase 2 (AcSOD2) [26].

Although intense inflammatory responses triggered by MI are essential for cardiac repair, they could be implicated in the pathogenesis of post-infarction remodeling and heart failure. Having anti-inflammatory effects, curcumin is currently being used to attenuate the inflammation and thereby suppress the activation of a pro-fibrotic program [27]. In this regard, Lv et al. assessed the molecular mechanisms involved in curcumin-reduced inflammation after myocardial injury in rats [28]. They showed that the administration of curcumin at a dosage of 150 mg/kg/body weight results in an improvement in cell survival, reduction of infiltration of inflammatory cells, and thereby a decrease in proliferation of fibrous tissue. Their results revealed that curcumin exerts its anti-inflammatory effect through down-regulating the expression of nuclear factor- κ B (NF- κ B). Influence on the Nrf2-keap1 signaling pathway and suppression of the production of tumor necrosis factor (TNF) and the TNF-mediated cell signaling are also identified as other anti-inflammatory effects of curcumin [29,30].

Similar to the above-mentioned biological properties, anti-bacterial effects of biomaterials also are of great importance for cardiac tissue engineering. For instance, Mahmoudi et al. in 2016 developed infection-resistant MRI-visible patches for cardiac tissue engineering by incorporating superparamagnetic iron oxide nanoparticles (SPIONs) into this patch [31]. Based on the literature, it can be stated that curcumin possesses anti-bacterial features through the interaction with the essential cell division initiating protein FtsZ [32,33]. FtsZ is an essential protein in most prokaryotes, responding for bacterial cell division. It has been identified that the methoxy and hydroxyl groups of curcumin are indeed involved in its antimicrobial activity

[34,35]. The minimum inhibitory concentration (MIC) of curcumin has been previously evaluated on both Gram-positive and Gram-negative bacterial strains by Gunes et al. [36]. They reported that the curcumin showed anti-bacterial effects against *Pseudomonas aeruginosa* (175 mg/mL), *Bacillus subtilis* (129 mg/mL), methicillin-sensitive *Staphylococcus aureus* (219 mg/mL), methicillin-resistant *S. aureus* (217 mg/mL), *E. coli* (163 mg/mL), *Enterococcus faecalis* (293 mg/mL), and *Klebsiella pneumoniae* (216 mg/mL).

Figure 2. Schematic illustration of biological activities proposed for curcumin. Reproduced from Ref [37].

According to promising *in vitro* and *in vivo* results, pre- and clinical potential of curcumin has been evaluating in a large number of studies. For example, pharmacokinetic studies of curcumin were assessed in rodents like mouse, rat, and rabbit [38-42]. At the moment, near 198 clinical trials” (www.clinicaltrials.gov) on curcumin’s therapeutic benefits have been registered. Among them, 11 studies are found for curcumin applications in cardiovascular diseases.

2.2. The challenges ahead

Up to now, a couple of physico-chemical restrictions have been counted for the wide use of curcumin, including its poor water solubility under acidic or neutral conditions, high decomposition rate in alkaline media and photo-degradation in organic solvents [9]. Moreover, the quick degradation of curcumin at physiological pH is considered as another complication regarding its use in the biomedical applications. However, researchers could overcome these

obstacles by developing complex formulations of curcumin and different carrier macromolecules, such as alginate and other polymers [43,44].

The use of the right concentrations of any substance for cardiac tissue engineering strategies should be determined through well-defined in vitro and in vivo assays. Although curcumin has no mutagenic and carcinogenic effects and has been “generally recognized as safe” (GRAS) by the US Food and Drug Administration (FDA) [45], there are a couple of studies showing that curcumin at high concentrations could cause nuclear DNA fragmentation in mammalian cell lines [46]. Moreover, some experimental data clarified that curcumin could inhibit the activity of the drug-metabolizing enzymes cytochrome P450, glutathione-S-transferase, and UDP-glucuronosyltransferase, which can lead to an undesired increase in the plasma concentrations of some drugs and thereby cause toxicity [47].

3. Expert Opinion

Today, curcumin has been widely proposed for the repair and regeneration of both hard and soft tissues. Based on the desired tissue to heal, researchers have developed and prepared a number of curcumin-containing implantable systems like micro- or nano-sized spheres, fibrous constructs and three dimensional (3D) scaffolds [9]. The carrier materials hosting curcumin molecules are typically designed as temporary matrices that degrade in vivo over time allowing a local and prolonged release of the active agent, thus minimizing the negative effects related to systemic toxicity and maximizing the therapeutic efficacy in situ.

It is worth pointing out that, although curcumin-delivering implants have been already developed for use in wound applications and osteochondral regeneration [9], no systems have

been specifically proposed for cardiac tissue engineering so far. Looking at this promising field of research, polymeric biomaterials seem to exhibit the most suitable physico-mechanical characteristics to be used in contact with the soft and delicate structures of the heart. A range of synthetic polymers, such as poly(glycerol sebacate), poly(ethylene glycol), poly(glycolic acid), poly(lactic acid), polycaprolactone, and polyurethanes, have been variously processed to obtain cardiac patches (or scaffolds) [48,49]. However, strategies of surface functionalization should be carried out so that curcumin molecules can bind to or be somehow encapsulated into these polymeric matrices for subsequent release. Furthermore, it cannot be ignored that synthetic polymers used in cardiac applications are mostly hydrophobic and lack cell recognition sites; thus, biofunctionalization of these biomaterials is also to be applied to enhance cell attachment and cell-material interactions [50].

Given the tendency of curcumin to degrade at physiological pH, encapsulation in polymeric micro- or nano-spheres rather than binding to the exposed surface of polymeric patches could be preferable [51-54]. In this regard, administration of curcumin-loaded polymeric spheres via injection would deserve to be considered. Biocompatible hydrogels with tunable swelling properties, porosity, degradation kinetics and permeability to biological fluids, nutrients, and oxygen could be investigated as promising carriers for curcumin. More specifically, injectable and smart hydrogels able to change their properties in response to different stimuli (e.g., temperature and pH) [55], thereby allowing a targeted release of curcumin, would be highly appealing.

Apart from polymeric biomaterials, other inorganic platforms such as mesoporous bioactive glasses (MBGs) have been widely investigated as drug delivery systems in tissue

engineering applications [56,57]. Given their inherent physico-mechanical properties (e.g., high stiffness) and apatite-forming capability, they have been mostly proposed for bone regeneration; however, incorporation of MBGs in polymeric matrices has also been recently proposed in the context of soft tissue repair [58]. At present, there are no studies dealing with the specific usage of MBGs for cardiac tissue engineering, and only one report has been published about the release of curcumin from MBGs (in the context of bone repair) [59]. In general, an important aspect that deserves to be mentioned when using MBGs in contact with soft tissues (including heart) is the risk of soft tissue calcification associated with the inherent bioactivity of these materials.

Regardless of the type of carrier material used, the optimal dosage of curcumin for promoting the repair and regeneration of cardiac tissue is a critical issue that still has to be comprehensively investigated. Appropriate *in vitro* (with cells) and *in vivo* (animal) models should be developed to elucidate this point as well as to test the potentially-suitable curcumin-loaded platforms.

Conflict of interest:

The authors declare no conflict of interest.

References:

1. Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. *JRSM cardiovascular disease*, 6, 2048004016687211 (2017).
2. Kargozar S, Hamzehlou S, Baino F. Potential of Bioactive Glasses for Cardiac and Pulmonary Tissue Engineering. *Materials*, 10(12), 1429 (2017).
3. Boroumand S, Asadpour S, Akbarzadeh A, Faridi-Majidi R, Ghanbari H. Heart valve tissue engineering: An overview of heart valve decellularization processes. *Regenerative Medicine*, 13(1), 41-54 (2018).
4. Asadpour S, Yeganeh H, Ai J, Ghanbari H. A novel polyurethane modified with biomacromolecules for small-diameter vascular graft applications. *Journal of Materials Science*, 53(14), 9913-9927 (2018).
5. Alcon A, Cagavi Bozkulak E, Qyang Y. Regenerating functional heart tissue for myocardial repair. *Cellular and molecular life sciences : CMLS*, 69(16), 2635-2656 (2012).
6. Asadpour S, Yeganeh H, Ai J *et al.* Polyurethane-Polycaprolactone Blend Patches: Scaffold Characterization and Cardiomyoblast Adhesion, Proliferation, and Function. *ACS Biomaterials Science and Engineering*, 4(12), 4299-4310 (2018).
7. Reis LA, Chiu LL, Feric N, Fu L, Radisic M. Biomaterials in myocardial tissue engineering. *Journal of tissue engineering and regenerative medicine*, 10(1), 11-28 (2016).
8. Broughton KM, Wang BJ, Firouzi F *et al.* Mechanisms of cardiac repair and regeneration. *Circulation research*, 122(8), 1151-1163 (2018).
9. Ahangari N, Kargozar S, Ghayour-Mobarhan M *et al.* Curcumin in tissue engineering: A traditional remedy for modern medicine. *BioFactors*, 0(0) (2018).
10. Shakeri A, Ward N, Panahi Y, Sahebkar A. Anti-angiogenic activity of curcumin in cancer therapy: A narrative review. *Current vascular pharmacology*, 17(3), 262-269 (2019).
11. Montalbán M, Coburn J, Lozano-Pérez A, Cenis J, VÍllora G, Kaplan D. Production of curcumin-loaded silk fibroin nanoparticles for cancer therapy. *Nanomaterials*, 8(2), 126 (2018).
12. Kumar SU, Kumar V, Priyadarshi R, Gopinath P, Negi YS. pH-responsive prodrug nanoparticles based on xylan-curcumin conjugate for the efficient delivery of curcumin in cancer therapy. *Carbohydrate polymers*, 188, 252-259 (2018).

13. Kasi PD, Tamilselvam R, Skalicka-Woźniak K *et al.* Molecular targets of curcumin for cancer therapy: an updated review. *Tumor Biology*, 37(10), 13017-13028 (2016).
14. Wei Y, Pu X, Zhao L. Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy. *Oncology reports*, 37(6), 3159-3166 (2017).
15. Zhang Y, Yang C, Wang W *et al.* Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. *Scientific reports*, 6, 21225 (2016).
16. Danafar H, Davaran S, Rostamizadeh K, Valizadeh H, Hamidi M. Biodegradable m-PEG/PCL Core-Shell Micelles: Preparation and Characterization as a Sustained Release Formulation for Curcumin. *Advanced pharmaceutical bulletin*, 4(Suppl 2), 501-510 (2014).
17. Kheiri Manjili H, Ghasemi P, Malvandi H, Mousavi MS, Attari E, Danafar H. Pharmacokinetics and in vivo delivery of curcumin by copolymeric mPEG-PCL micelles. *European Journal of Pharmaceutics and Biopharmaceutics*, 116, 17-30 (2017).
18. Perrone D, Ardito F, Giannatempo G *et al.* Biological and therapeutic activities, and anticancer properties of curcumin. *Experimental and therapeutic medicine*, 10(5), 1615-1623 (2015).
19. Uğuz AC, Öz A, Nazıroğlu M. Curcumin inhibits apoptosis by regulating intracellular calcium release, reactive oxygen species and mitochondrial depolarization levels in SH-SY5Y neuronal cells. *Journal of Receptors and Signal Transduction*, 36(4), 395-401 (2016).
20. Wang J, Wang H, Zhu R, Liu Q, Fei J, Wang S. Anti-inflammatory activity of curcumin-loaded solid lipid nanoparticles in IL-1 β transgenic mice subjected to the lipopolysaccharide-induced sepsis. *Biomaterials*, 53, 475-483 (2015).
21. Lundvig DM, Pennings SW, Brouwer KM *et al.* Curcumin induces differential expression of cytoprotective enzymes but similar apoptotic responses in fibroblasts and myofibroblasts. *Experimental cell research*, 330(2), 429-441 (2015).
22. Levraut J, Iwase H, Shao Z-H, Vanden Hoek TL, Schumacker PT. Cell death during ischemia: relationship to mitochondrial depolarization and ROS generation. *American Journal of Physiology-Heart and Circulatory Physiology*, 284(2), H549-H558 (2003).
23. Panth N, Paudel KR, Parajuli K. Reactive oxygen species: a key hallmark of cardiovascular disease. *Advances in medicine*, 2016 (2016).
24. Liu H, Wang C, Qiao Z, Xu Y. Protective effect of curcumin against myocardium injury in ischemia reperfusion rats. *Pharmaceutical biology*, 55(1), 1144-1148 (2017).
25. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. *Circulation*, 91(10), 2504-2507 (1995).

26. Wang R, Zhang J, Zhang M *et al.* Curcumin attenuates IR-induced myocardial injury by activating SIRT3. *European review for medical and pharmacological sciences*, 22, 1150-1160 (2018).
27. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. *Nature reviews. Cardiology*, 11(5), 255-265 (2014).
28. Lv FH, Yin HL, He YQ *et al.* Effects of curcumin on the apoptosis of cardiomyocytes and the expression of NF- κ B, PPAR- γ and Bcl-2 in rats with myocardial infarction injury. *Experimental and therapeutic medicine*, 12(6), 3877-3884 (2016).
29. Chang N-S, Joki N, Mattison J, Dinh T, John S. Characterization of serum adhesive proteins that block tumor necrosis factor-mediated cell death. *Cell death and differentiation*, 4(8), 779 (1997).
30. Gupta SC, Tyagi AK, Deshmukh-Taskar P, Hinojosa M, Prasad S, Aggarwal BB. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. *Archives of biochemistry and biophysics*, 559, 91-99 (2014).
31. Mahmoudi M, Zhao M, Matsuura Y *et al.* Infection-resistant MRI-visible scaffolds for tissue engineering applications. *BioImpacts: BI*, 6(2), 111 (2016).
32. Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. *BioMed research international*, 2014 (2014).
33. Rai D, Singh JK, Roy N, Panda D. Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity. *Biochemical Journal*, 410(1), 147-155 (2008).
34. Han S, Yang Y. Antimicrobial activity of wool fabric treated with curcumin. *Dyes and pigments*, 64(2), 157-161 (2005).
35. Tesaki S, Tanabe S, Ono H, Fukushi E, Kawabata J, WATANABE M. 4-Hydroxy-3-nitrophenylacetic and sinapic acids as antibacterial compounds from mustard seeds. *Bioscience, biotechnology, and biochemistry*, 62(5), 998-1000 (1998).
36. Gunes H, Gulen D, Mutlu R, Gumus A, Tas T, Topkaya AE. Antibacterial effects of curcumin: an in vitro minimum inhibitory concentration study. *Toxicology and industrial health*, 32(2), 246-250 (2016).
37. Gera M, Sharma N, Ghosh M *et al.* Nanoformulations of curcumin: an emerging paradigm for improved remedial application. *Oncotarget*, 8(39), 66680 (2017).
38. Chen H, Yang X, Lu K *et al.* Inhibition of high glucose-induced inflammation and fibrosis by a novel curcumin derivative prevents renal and heart injury in diabetic mice. *Toxicology letters*, 278, 48-58 (2017).

39. Xiao J, Sheng X, Zhang X, Guo M, Ji X. Curcumin protects against myocardial infarction-induced cardiac fibrosis via SIRT1 activation in vivo and in vitro. *Drug design, development and therapy*, 10, 1267-1277 (2016).
40. Yeh C-H, Lin Y-M, Wu Y-C, Lin PJ. Inhibition of NF- κ B activation can attenuate ischemia/reperfusion-induced contractility impairment via decreasing cardiomyocytic proinflammatory gene up-regulation and matrix metalloproteinase expression. *Journal of cardiovascular pharmacology*, 45(4), 301-309 (2005).
41. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *The International Journal of Biochemistry & Cell Biology*, 41(1), 40-59 (2009).
42. Srivastava G, Mehta JL. Currying the heart: curcumin and cardioprotection. *Journal of cardiovascular pharmacology and therapeutics*, 14(1), 22-27 (2009).
43. Hjorth Tønnesen H. Solubility and stability of curcumin in solutions containing alginate and other viscosity modifying macromolecules-Studies of curcumin and curcuminoids. *Die Pharmazie-An International Journal of Pharmaceutical Sciences*, 61(8), 696-700 (2006).
44. Sarika P, James NR. Polyelectrolyte complex nanoparticles from cationised gelatin and sodium alginate for curcumin delivery. *Carbohydrate polymers*, 148, 354-361 (2016).
45. Balaji S, Chempakam B. Toxicity prediction of compounds from turmeric (*Curcuma longa* L). *Food and Chemical Toxicology*, 48(10), 2951-2959 (2010).
46. Ting C-Y, Wang H-E, Yu C-C, Liu H-C, Liu Y-C, CHIANG I-T. Curcumin triggers DNA damage and inhibits expression of DNA repair proteins in human lung cancer cells. *Anticancer research*, 35(7), 3867-3873 (2015).
47. Mancuso C, Barone E. Curcumin in clinical practice: myth or reality? *Trends in pharmacological sciences*, 30(7), 333-334 (2009).
48. Chen Q-Z, Harding SE, Ali NN, Lyon AR, Boccaccini AR. Biomaterials in cardiac tissue engineering: ten years of research survey. *Materials Science and Engineering: R: Reports*, 59(1-6), 1-37 (2008).
49. Danafar H. Study of the composition of polycaprolactone/poly (ethylene glycol)/polycaprolactone copolymer and drug-to-polymer ratio on drug loading efficiency of curcumin to nanoparticles. *Jundishapur Journal of Natural Pharmaceutical Products*, 12(1) (2017).
50. Tallawi M, Rosellini E, Barbani N *et al.* Strategies for the chemical and biological functionalization of scaffolds for cardiac tissue engineering: a review. *Journal of the Royal Society Interface*, 12(108), 20150254 (2015).

51. El Khoury ED, Patra D. Ionic liquid expedites partition of curcumin into solid gel phase but discourages partition into liquid crystalline phase of 1, 2-dimyristoyl-sn-glycero-3-phosphocholine liposomes. *The Journal of Physical Chemistry B*, 117(33), 9699-9708 (2013).
52. Moussa Z, Chebl M, Patra D. Fluorescence of tautomeric forms of curcumin in different pH and biosurfactant rhamnolipids systems: application towards on-off ratiometric fluorescence temperature sensing. *Journal of Photochemistry and Photobiology B: Biology*, 173, 307-317 (2017).
53. Danafar H. Applications of copolymeric nanoparticles in drug delivery systems. *Drug research*, 66(10), 506-519 (2016).
54. Gharebaghi F, Dalali N, Ahmadi E, Danafar H. Preparation of wormlike polymeric nanoparticles coated with silica for delivery of methotrexate and evaluation of anticancer activity against MCF7 cells. *Journal of biomaterials applications*, 31(9), 1305-1316 (2017).
55. Soppimath KS, Aminabhavi TM, Dave AM, Kumbar SG, Rudzinski W. Stimulus-responsive "smart" hydrogels as novel drug delivery systems. *Drug development and industrial pharmacy*, 28(8), 957-974 (2002).
56. Wu C, Chang J. Multifunctional mesoporous bioactive glasses for effective delivery of therapeutic ions and drug/growth factors. *Journal of controlled release*, 193, 282-295 (2014).
57. Kargozar S, Montazerian M, Hamzehlou S, Kim H-W, Baino F. Mesoporous bioactive glasses: Promising platforms for antibacterial strategies. *Acta Biomaterialia*, 81, 1-19 (2018).
58. Kargozar S, Hamzehlou S, Baino F. Can bioactive glasses be useful to accelerate the healing of epithelial tissues? *Materials Science and Engineering: C*, 97, 1009-1020 (2019).
59. Shruti S, Salinas AJ, Ferrari E *et al.* Curcumin release from cerium, gallium and zinc containing mesoporous bioactive glasses. *Microporous and Mesoporous Materials*, 180, 92-101 (2013).

Figure caption:

Figure 1. Representative illustration of mechanisms involved in cardiac tissue repair and regeneration. Reproduced from Ref [8].

Figure 2. Schematic illustration of biological activities proposed for curcumin. Reproduced from Ref [29].